Pharmacoeconomic modelling in schizophrenia: Trap or support for decision makers?

European Journal of Health Economics

Volumn 7, Issue 1, 2006, Pages 19-29

  Hansen, Karina ^a,c   Lançon, Christophe ^b   Toumi, Mondher ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c Lundbeck   (France)

Author keywords

Atypical antipsychotic; Cost effectiveness analysis; Economic modelling; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZUCLOPENTHIXOL;

COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG SUBSTITUTION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMETRIC; PATIENT COMPLIANCE; PATIENT DROPOUTS; RECURRENCE; SCHIZOPHRENIA;

EID: 33644866651     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-005-0326-x     Document Type: Review

References (44)

1. Caroff SN, Mann SC, Campbell EC, Sullivan K (2002) Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63 [Suppl 4]:12-19
2. Conley RR, Kelly DL (2002) Current status of antipsychotic treatment. Curr Drug Targets CNS Neurol Disorders 1:123-128
3. Möller HJ (2003) Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 17(11):793-823
4. Genduso LA, Hakey JC (1997) Cost of illness studies for schizophrenia: components, benefits, results, and implications. Am J Manag Care 3:873-877
5. Salize HJ, Rössler W (1996) The cost of comprehensive care of people with schizophrenia living in the community - a cost evaluation from a German catchment area. Br J Psychiatry 169:42-48
6. Rouillon F, Toumi M, Dansette GY, Benyaya J, Auquier P (1997) Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 11(6):578-594
7. Masand PS, Berry SL (2000) Switching antipsychotic therapies. Ann Pharmacotherapy 34:200-207
8. Masand PS (1998) Weight gain associated with atypical antipsychotics. J Psychotic Disorder 2:4-6
9. Beasley CM, Tollefson GD, Tran PV (1998) Safety of olanzapine. J Clin Psychiatry 58 [Suppl. 10]:13-17
10. th Annual Meeting of the American College of Neuropsychopharmacology, Kamuela, Hawaii
11. Souêtre E, Martin P, Lecanu JP, Alexandre L, Lozet H, Gauthier JM, Camus C (1992) Economic assessment of neuroleptic strategies in schizophrenia: amisulpride versus halopéridol. L'Encéphale 18:263-269 [French]
12. Fichtner CG, Hanrahan R Luchins DJ (1998) Pharmacoeconomic studies of atypical antipsychotics: review and perspective. Psychiatric Annals 28(7):381-396
13. Beck JR, Pauker SG (1983) The Markov process in medical prognosis. Med Decis Making 3:419-458
14. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322-338
15. Drummond MF, O'Brien B, Stoddart GL, Torrance G (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford
16. Weiden PJH, Mott T, Curcio N (1995) Recognition and management of neuroleptic noncompliance. In: Shriqui CL, Nasrallah HA (eds) Contemporary issues in the treatment of schizophrenia. American Psychiatric Press, Washington, DC, pp 411-434
17. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ (2000) Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 51(2):216-222
18. Rittmannsberger H, Pachinger T, Keppelmüller P, Wancata J (2004) Medication adherence among psychiatric patients before admission to inpatient treatment. Psychiatr Serv 55(2):174-179
19. Lundbeck H A/S. Data on file, available on request from corresponding author
20. Langley-Hawthorne C (1997) Modeling the life-time costs of treating schizophrenia in Australia. Clin Ther 19(6):1470-1495
21. Mauskopf JA, David K, Grainger DL, Gibson PJ (1999) Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry 60 [Suppl 19]:14-19
22. Foster RH, Goa KL (1999) Olanzapine: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 15(6):611-640
23. Oh PI, Iskedjian M, Addis A, Lanctôt K, Einarson TR (2001) Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol 8(4):199-206
24. Almond S, O'Donnell O (1998) Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapineand haloperidol. Pharmacoeconomics 13(5 Pt 2):575-588
25. Glennie JL (1997) Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Technology overview: pharmaceuticals. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa, issue 7.0
26. Sacristián JA, Gomez JC, Salvador-Carulla L (1997) Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain. Actas luso-españolas de neurologia, psiquiatría y ciencias afines 25(4):225-234 [Spanish]
27. Guest JF, Cookson RF (1999) Cost of schizophrenia to UK society. Pharmacoeconomics 15:597-610
28. Duggan A, Warner J, Knapp M, Kerwin R (2003) Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 182:505-508
29. Davies LM, Drummond MF (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 162:38-42
30. Glazer WM, Ereshefsky L (1996) A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 57(8):337-345
31. Laurier C, Kennedy W, Lachaine J, Gariepy L, Tessier G (1997) Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis. Clin Ther 19(2):316-329
32. Byrom B, Garratt C, Kilpatrick AT (1998) Influence of antipsychotic profile on cost of treatment of schizophrenia: a decision analysis approach. Int J Psychiatry 2:129-138
33. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE (1998) A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 4(3):345-355
34. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I (1998) Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther 20(1):196-213
35. Launois R, Graf von der Schulenberg M, Knapp M, Toumi M (1998) Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model. Int J Psychiat Clin Pract 2 [Suppl 2]:79-86
36. Almond S, O'Donnell O (2000) Cost analysis of the treatment of schizophrenia in the UK: a simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 17(4):383-389
37. Lecomte P, De Hert M, Dijk MV, Nuijten M, Nuyts G, Persson U (2000) A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health 3(1):1-11
38. Tilden D, Aristides M, Meddis D, Burns T (2002) An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin Ther 24(10):1648-1667
39. Emsley RA, Raniwalla J, Bailey PJ, Jones AM on behalf of the PRIZE Study Group (2000) A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 15:121-131
40. Ganguly R, Miller LS, Martin BC (2003) Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr Res 63:111-119
41. National Institute for Clinical Excellence (2004) Guide to the methods of technology appraisal. Oxford, Radcliffe Medical Press
42. Dalkey N, Helmer O (1963) An experimental application of the Delphi method to the use of experts. Man Sci 9(3):458-467
43. Evans C, Crawford B (2000) Expert judgement in pharmacoeconomic studies. Guidance and future use. Pharmacoeconomics 17(6):545-553
44. Nuijten MJC (1999) Measuring sensitivity in pharmacoeconomic studies-refining point sensitivity and range sensitivity by incorporating probability distributions. Pharmacoeconomics 16(1):33-41